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ABSTRACT  
Vomiting or emesis is the abnormal emptying of stomach and upper part of intestine through esophagus and mouth. It occurs due to stimulation 
of the emetic (vomiting) centre situated in the medulla oblongata. Domperidone, a D2 receptor antagonist has antiemetic and prokinetic action 
is used as a model drug in the present work to prepare Sustained release matrix tablets using various synthetic polymers like Eudragit and 
HPMC K15 M. The tablets are designed to have a pH dependent release profile in order to prevent initial drug release in the stomach to reduce 
the possible gastro-irritant and ulcerogenic effects of the drug. Different polymer and diluent concentrations and various compression 
techniques like wet granulation technique and direct compression techniques were used in order to release the contents of the tablets in a 
sustained manner over a certain period of time. Domperidone is BCS Class II drug and its solubility was enhanced by preparing solid 
dispersions using solvent evaporation technique. In the present work solid dispersions containing drug and polymer mixture in the ratio 1:1 
was further formulated into tablets by incorporating various synthetic polymers in three different concentrations. The tablets were prepared 
using different granulating techniques. Formulation (F3) containing drug and  polymers in the ratio 1:1 prepared by wet granulation technique 
could sustain the drug release over a period of 12h and hence considering all the post compression parameters it was optimized as the better 
formulation. FTIR, DSC, X-Ray Diffraction, SEM studies were performed for optimized solid dispersion mixture and also the optimized 
formulation. 
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Oral drug delivery has been the most widely preferred route 
of administration among all the routes for the systemic 
delivery of drugs from various pharmaceutical products or 
different dosage forms. Nowadays most of the 
pharmaceutical scientists are involved in developing ideal 
Drug Delivery Systems. This ideal system should have an 
advantage that a single dose should deliver the drug directly 
at specific site for whole duration of the treatment. The aim 
in designing sustained delivery systems is to reduce the 
frequency of the dosing and to increase effectiveness of the 
drug by localization at the site of action. [1]  
There has been a profound increase in the development of 
sustained release drug delivery system in the last two 
decades due to various reasons like expiration of various 
international patents, prohibitive cost of developing new 
drug entities, discovery of new polymeric materials that are 
suitable for retarding the release of the drug, improvement 
in therapeutic efficiency and safety [2]. Of all sustained 
release dosage forms, matrix tablets are considered to be the 
commercially feasible dosage forms that involve the least 
processing variables, utilize the conventional facilities and 
accommodate large doses of drug. Matrix devices had gained 
steady popularity in pharmaceutical research due to their 
chemical inertness, drug embedding ability and drug release 
character [3]. 
Vomiting is regulated centrally by the vomiting centre and 
the chemoreceptor trigger zone (CTZ), which are present in 
the medulla. The CTZ is sensitive to chemical stimuli and is 
the main site of action of many emetic and antiemetic drugs. 
Dopamine (acting through D2 receptors) is an inhibitory 
transmitter in the GIT normally acts to delay gastric 
emptying when food is present in stomach. It also appears to 
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cause gastric dilation and LES relaxation attending nausea 
and vomiting [4]. Domperidone blocks D2 receptors and has 
an opposite effect-hastening gastric emptying and enhancing 
LES tone by augmenting Ach release, clinically this action is 
exerted through 5HT receptors. The central anti dopamergic 
action on CTZ responsible for anti-emetic property [5] 
The main aim of the present work is to formulate and 
evaluate sustained release matrix tablets of Domperidone by 
using natural polymers like Eudragit RS 100 and HPMC 
K15M using various compression techniques like wet 
granulation technique and direct compression techniques.  
MATERIALS AND METHODS: 
Materials: 
Domperidone, Eudragit RS 100, and Hydroxyl propyl methyl 
cellulose K15M, ß cyclodextriene and Lacctose were 
obtained from Yarrow chem products, Mumbai. Talc was 
obtained from Otto Chemika Biochemika reagents. 
Method: 
Domperidone a BCS class II drug is poorly soluble in water. 
Therefore, solubility of Domperidone was enhanced by 
preparing solid dispersions using solvent evaporation 
technique. Solvent evaporated mixtures were formulated by 
using drug and carrier in different ratios such as 1:0.75, 1:1 
1:1.5. Dissolution studies were performed for the solvent 
evaporated mixtures using USP dissolution type II apparatus 
(paddle method) at 50 rpm using 6.8pH phosphate buffer as 
dissolution medium at 37±0.5oC. Based on physicochemical 
characterization, solvent evaporated mixture containing 
drug and carrier in the ratio of 1:1 (equivalent to 30mg of 
drug) was selected to formulate into sustain release tablets.
 
Table 1: Formulation table for Solid Dispersions 
Formulation code Carriers Method Drug: Polymer ratio 
SD 1 HP-β-CD Solvent evaporation 1: 0.75 
SD 2 HP-β-CD Solvent evaporation 1: 1 
SD 3 HP-β-CD Solvent evaporation 1:1.5 
                   
Sustained release matrix tablets of Domperidone were prepared by using direct compression technique and wet granulation 
techniques. The optimized mixtures were characterized by FTIR spectroscopy, DSC studies, X-ray diffraction etc. 
Table 2: Formulation table for Preparation of tablets: 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Method Wet Granulation Method Direct Compression Method 
Domperidone  30 30 30 30 30 30 30 30 30 30 30 30 
HPMC K15 M 7.5 15 30 - - - 7.5 15 30 - - - 
Eudragit RS100 - - - 7.5 15 30 - - - 7.5 15 30 
Lactose 158 150 -- 158 150 135.5 158 150 135.5 158 150 135.5 
Mg Stearate 3 3 3 3 3 3 3 3 3 3 3 3 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
 
Direct Compression Technique: All the ingredients were 
weighed separately dried for 30 mins at 50°C and cooled to 
room temperature. They were then passed through #40 
sieve separately to attain fine powder. The sieved powders 
were weighed and added geometrically (except glidant and 
lubricant), mixed   properly and then finally lubricant and 
talc were added just before compression. This mixture was 
directly compressed using rotary tablet punching machine 
equipped with 8mm flat faced circular punches at a constant 
compression force.[6] 
Wet Granulation Technique: In this technique all the 
ingredients except lubricants and anti- adherent were mixed 
properly and then the mixture is formed into dough using 
2% starch paste as a binding agent. Then the dough is then 
passed through the sieve #22 to form the granules. The so 
formed granules were dried at 50°C and then cooled at room 
temperature. Lubricant and glidant were added. Then the 
mixture was compressed using rotary   tablet punching 
machine equipped with 8mm flat faced circular punches at a 
constant compression force.[7] 
 
Evaluation Parameters: 
Pre Compression Parameters: 
Prior to the compression of tablets, the blend of drug and 
excipients of all the batches were evaluated for various 
micromeritic properties like Angle of repose, bulk density, 
tapped density, Carr’s Compressibility index and Hausner’s 
ratio.[8] 
Post Compression Parameters: 
Thickness: Thickness of the sustained release tablets were 
tested using calibrated Vernier-calipers. The tablet thickness 
was controlled within a ±5% variation. 
Hardness test or crushing strength:Hardness is the force 
required to break a tablet across the diameter. It is measured 
in kilograms and a crushing strength of usually 4kg is 
considered to be the minimum satisfactory for tablets. The 
hardness was tested using Monsanto hardness tester. 
Friability test: This is an in process quality control test 
performed to ensure the ability of tablets to withstand 
shocks during processing, handling, transportation, and 
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shipment. It is usually measured by using Roche 
Friabilator.[9] 
% friability =
             –           
             
 × 100 
Uniformity of weight or Weight variation test: This test is 
performed to check the weight of the tablet frequently (every 
half an hour) so that in case of any corrections will be made 
during the compression of tablets. Any variation in the 
weight of the tablet may lead to over dose or under dose of 
medication. Therefore every tablet in each batch should have 
a uniform weight.[10] 
% deviation= [(individual weight-average weight)] /average 
weight×100 
Estimation of drug content: Drug   content was determined 
accurately by weighing 5 tablets and crushing them in motor 
with the help of a pestle. Content uniformity was calculated 
using the following formula. 
                                       % purity =10 C (Au/As) 
Where, C= Concentration, Au and As= absorbance obtained 
from the standard preparation and assay preparation 
respectively. 
In–vitro drug release studies:  
The dissolution behaviour of Domperidone was recorded 
using a dissolution apparatus (Disso 2000 LAB INDIA, 
Mumbai). USP dissolution apparatus with rotating paddle 
assembly (type II) was used at 50 rpm, in 900 ml of 
deionised water (phosphate buffer pH 6.8). The mean of the 
three determinations was used to calculate the drug release 
from the tablets. The samples were withdrawn at 
predetermined time intervals, and equal amount of fresh 
buffer was replaced. The obtained samples were filtered and 
assayed spectrophotometrically at 285nm.[11] 
FT-IR Study:  
The FT-IR spectra of pure drug, polymers and optimized 
formulation were scanned over a frequency range 4000-400 
cm-1 by placing sample on diamond ATR and analyzing for 
the presence of characteristic peaks.[12] 
Thermal Analysis: 
DSC was performed using DSC calorimeter to study the 
thermal behavior of pure drug, polymers and mixture of 
optimized formulation. The required amounts of samples 
were heated in sealed aluminium pans under nitrogen flow 
(30ml/min) at a scanning rate 5°C per min from 40°C to 
250°C. The heat flow as a function of temperature and 
enthalpy change was measured for the drug, polymers and 
mixture of optimised formulation. [13] 
X-ray diffraction analysis:  
X-ray diffraction is an important tool to investigate the 
crystal structure as well as the average structural spacing 
between the layers or rows of atoms in an unknown material. 
Formulations were subjected to X-ray diffraction analysis, 
using Cu target slit 10 mm to investigate the physical state of 
Domperidone, HP-β-CD and Domperidone solvent 
evaporated mixtures.[14] 
Scanning Electron Microscopy: 
Scanning electron microscope (SEM) allows viewing and 
surface analysis of solid dispersions as well as spatial pattern 
formation for the scanned object. This is very important for 
the qualitative assessment of their properties such as 
particle size, their shape, morphology, porosity, presence of 
crystalline forms, as well as tested powders texture 
monitoring.[15] 
RESULTS 
Characterization of pure drug Domperidone: 
Identification of Domperidone by UV- visible 
spectrophotometer: Standard plot of Domperidone was 
constructed by taking series of concentration in pH 6.8 
phosphate buffer and pH  1.2 N  HCl   buffer. The absorption 
spectra were recorded in the wavelength region of 200-400 
nm in the UV visible spectrophotometer. The absorption 
maximum of Domperidone was found to be 285 nm. 
Melting point: Melting point of Domperidone was 
determined using melting point apparatus and DSC. The 
temperature at which the drug starts to melts is recorded 
and compared to its standard value. Melting point of 
Domperidone was found to be 245.98°C by DSC and 242-
246°C by melting method, which complies with the standard 
values in the official monograph as per USP- NF. The above 
determined results show the drug is pure and free from 
impurities.[16] 
Solubility: Solubility determination of Domperidone was 
carried out in water and organic solvents. As it is class II 
drug, Domperidone shows poor solubility. It was found that 
Domperidone is practically insoluble in water, but soluble in 
organic solvents like ethanol, dimethylsulfoxide. The above 
estimation done was beneficial for further studies.[17] 
Compatibility studies of solid dispersions:    
Visual inspection: Visual inspections were conducted to 
check the compatibility between drug and excipients in its 
physical mixture when stored in glass container at room 
temperature for a certain period of time. The main objective 
of this inspection was to observe any colour change in the 
physical mixture. Throughout the examination, there was no 
change in the colour of the physical mixture throughout the 
examination period, indicating that drug and excipients are 
quite compatible each other. 
FTIR (Fourier transformer infrared spectroscopy): The 
physical mixture of drug and excipients was characterized by 
FTIR spectrum by yris Diamond TG/ DTA. The FTIR of the 
pure drug and solid dispersion did not show any peak 
indicating the absence of any chemical reaction between 
Domperidone and β-cyclodextrin  
DSC (Differential scanning Calorimetry): DSC thermogram 
of Domperidone showed a sharp peak at due to the melting 
point of the drug and indicating its crystalline nature. This 
shows that the drug considered for the research is in pure 
form. The measured melting endotherm of the β- 
cyclodextrin is 91.27°C. 
XRD (X-ray diffraction): The X-ray diffractograms of 
Domperidone showed characteristics sharp intensity 
diffraction peaks at 27.353°C 
Determination of drug content and percent yield in solid 
dispersions: 
All the solid dispersions prepared by solvent evaporation 
method were in the form of free flowing powders. The values 
of % drug content and % yield values were determined. 
 In-Vitro Dissolution Studies of SD’S: The in vitro 
dissolution studies were performed for the solid dispersions. 
The drug release from solid dispersions was 72.8, 97.53, and 
85.51% respectively in 1 hr. 
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Table 3: In vitro dissolution profile for solid dispersions 
Time (mins)       SD 1      SD 2       SD 3 
5 33.69±1.534 45.68±2.92 35.4±1.98 
10 42.31±2.630 55.35±1.31 49.9±2.41 
15 50.49±0.75 63.21±3.0 54.32±3.06 
30 56.36±1.26 79.58±3.92 67.49±2.91 
45 65.39±1.06 88.48±3.40 72.51±2.41 
60 72.8±2.08 97.53±3.16 85.51±3.57 
 
From the above data Solid dispersion SD2 was optimized as 
the best formulation and was further compressed into 
tablets. 
Precompression Parameters 
Precompression studies are conducted in order to determine 
the flow-ability, compressibility studies of the powder blend 
and granules. 
Different tablet batch formulations F1-F6 were prepared by 
wet granulation and F7–F12 by direct compression methods. 
Solid dispersion mixture (75mg) and other all excipients 
were passed individually through #40 sieve and mixed well 
for 10 min in a mortar and pestle to form a powder blend. 
This blend was compressed into tablets by wet granulation 
and direct compression techniques using single punch rotary 
tablet punching machine using 8mm flat punches. 
  
 










Friability (%) Drug content (%) 
F1 5.5±2.39 203.4±2.51 6.5±2.05 0.78±2.54 98.56±2.18 
F2 5.2±2.45 201.5±2.26 7.5±2.40 0.61±2.54 99.56±2.11 
F3 5.3±2.30 195.5±2.54 8±2.51 0.65±2.11 98.45±2.14 
F4 5.4±2.12 199.5±2.51 8.5±2.25 0.83±2.04 99.05±2.16 
F5 5.6±2.19 204.5±2.45 7.5±2.39 0.64±2.18 97.52±2.15 
F6 5.5±2.12 200±2.54 6.5±2.29 0.65±2.31 98.54±2.11 
F7 5.5±2.35 203.4±2.51 6.5±2.05 0.68±2.54 98.36±2.13 
F8 5.2±2.42 201.5±2.26 7.5±2.30 0.61±2.54 99.96±2.12 
F9 5.3±2.25 198.5±2.54 8±2.21 0.75±2.11 100.96±2.15 
F10 5.4±2.18 196.5±2.51 8.5±2.20 0.73±2.04 99.21±2.25 
F11 5.6±2.14 202.5±2.45 7.5±2.21 0.64±2.12 98.56±2.26 
F12 5.5±2.12 197.5±2.54 6.5±2.29 0.65±2.41 99.56±2.25 
 
 
In-vitro drug release studies: 
Prepared tablets were evaluated by conventional In-vitro 
dissolution testing USP type II apparatus at 50 rpm. Initially 
the dissolution studies were out in 900 ml of 0.2 N HCl for 2 
hours. After the completion of the 2 hours the remaining 
time period i.e., 10 hours the dissolution studies were 
performed in 6.8 pH phosphate buffer. Both the media was 
maintained at the temperature 37±5°C. The volume in order 
to maintain the sink condition; 5 ml of the dissolution media 
was withdrawn at the predetermined intervals and fresh 
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Table 5: In vitro dissolution profile of Domperidone Sustained release tablets by wet granulation and Direct 
Compression Techniques. 
Time F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
 Wet granulation Technique Direct Compression Technique 
1  5.96±1.4 7.42±1.2 8.01±1.9 10.52±1.3 9.62±1.5 10.56±1.2 7.56±1.2  14.68±1.5  15.58±1.2  14.52±1.2  19.52±1.2  16.46±1.2  
2 14.64±1.2 19.44±1.5 16.03±1.2 18.26±2.3 21.45±1.6 25.44±1.3 12.56±1.3  15.51±1.6  19.21±1.3  20.21±1.3  22.52±1.6  22.51±1.3  
3 25.4±2.1 30.48±1.3 28.8±1.3 27.56±1.4 31.62±1.4 35.65±1.4 28.45±1.3 31.56±1.2 31.52±1.4  32.25±1.4  29.56±1.4  32.52±1.3  
4 34.21±2.5 36.04±1.2 39.62±1.5 38.52±1.5 38.52±1.2 49.26±1.4 43.21±1.5 45.25±1.3 43.52±1.5  44.23±1.5  33.56±1.2  33.64±1.2  
5 49.25±1.7 40.06±1.6 48.58±1.7 48.29±1.6 41.25±1.3 55.26±1.3 71.56±1.2 69.72±1.5 52.56±1.5  55.56±1.4  40.56±1.5  44.42±1.4  
6 59.52±1.3 47.96±1.3 59.04±1.6 54.65±1.5 43.21±1.6 58.36±1.3 88.86±1.5 81.54±1.3 68.52±1.4  69.72±1.6  56.21±1.3 49.51±1.3  
7 65.21±1.6 59.41±1.4 65.82±1.5 68.25±1.7 48.54±1.6 63.24±1.6 98.32±1.8 95.56±1.5 85.86±1.5 73.59±1.8  67.56±1.5  56.52±1.2  
8 88.92±1.5 69.54±1.4 73.21±1.4 85.86±1.5 54.52±1.2 69.71±1.6 - - 96.26±1.4 85.46±1.7  73.21±1.5  61.52±1.7  
9 96.42±1.4 72.51±1.7 80.21±1.5 93.34±1.4 61.65±1.2 74.21±1,8 - - - 97.26±1.4 86.39±1.9 66.21±1.4  
10        - 81.54±1.3 87.51±1.1 - 65.66±1.3 83.52±1.6 - - - - 94.22±1.5 71.52v1.5  
11 - 92.22±2.3 91.56±1.5 - 69.24±1.5 89.51±1.3 - - - - - 75.21±1.5  




Fig 1: FTIR spectrum of Optimised Formulation 
 
 
Fig 2: DSC thermo gram of Optimized formulation 
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Fig 3: XRD of Optimised formulation 
 
 
Fig 4: SEM image of Solid Dispersion  mixture 
 
Fig 5: SEM image of optimized drug mixture 
DISCUSSION: 
Domperidone is a BCS Class II drug, having less solubility 
and more permeability. Therefore, the solubility of 
Domperidone was enhanced by preparing solid dispersions 
using solvent evaporation technique. β-cyclodextrin 
inclusion complexes were prepared in three different ratios 
like 1:0.75,1:1,1:1.5. In the present work drug:polymer in the 
ration 1:1 which showed 97% of drug release in 1 hour was 
optimized as the best mixture and further formulated into 
tablets by incorporating synthetic polymers in three 
different ratios using  wet granulation and direct 
compression techniques. 
The active pharmaceutical ingredient Domperidone was 
evaluated for its physical characteristics and drug polymer 
compatibility studies. The precompression powder blends of 
different batches were evaluated for various parameters like 
angle of repose, bulk density, tapped density, compressibility 
index Hausner’s ratio. The results obtained were found to be 
satisfactory and within the specified limits. 
The matrix tablets were prepared by wet granulation (F1-
F6) and direct compression (F7-F12) containing different 
ratios of drug and polymer were subjected to various 
evaluation tests such as thickness, uniformity of weight, drug 
content, hardness and friability. The results have complied 
with the official pharmacopeial limits. It has been observed 
in this investigation that the formulation (F3) containing 
drug and HPMC K15M  in the ratio 1:1 prepared by wet 
granulation technique could sustain the drug release over a 
period of 12h and hence considering all the post 
compression parameters it was optimized as the better 
formulation. 
CONCLUSION: 
Domperidone a BCS class II drug having low solubility and 
highly permeability was the drug of choice in the present 
study. It is mainly used in the treatment of Emesis and has a 
strong affinity for D2 receptors, chemically related to 
Haloperide, but pharmacologically related to 
Metaclopramide. Sustained release tablet of Domperidone is 
preferred because of its prolonged drug release manner, and 
therefore frequency of the dosing can be reduced. 
In the present study, it was decided to design controlled 
release formulation of Domperidone with pH dependent 
release profile so as to prevent initial drug release in the 
stomach that will reduce the possible gastro-irritant and 
ulcerogenic effects of the drug. At the same time, there was 
no compromise on the biopharmaceutical profile of the drug 
as Domperidone is reported to be well absorbed throughout 
the GI tract by increasing the half-life eventually producing 
the sustained action. This gives advantage in reducing the 
frequency of the dosage to increase effectiveness of the drug 
by localizing at the site of action.  
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